Progress of SLC7A5 in breast cancer
10.3760/cma.j.cn115355-20241219-00579
- VernacularTitle:SLC7A5在乳腺癌中的研究进展
- Author:
Xuejing WANG
1
;
Zhongwei CAO
Author Information
1. 内蒙古医科大学内蒙古临床学院，呼和浩特 010017
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
SLC7A5;
Metabolism;
Immunity;
Targeted therapy
- From:
Cancer Research and Clinic
2025;37(7):557-560
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of breast cancer remains high worldwide, which seriously threatens women's health. Many patients has benefited from the traditional way of surgery combined with drug therapy, but the drug resistance and side effects have made the treatment outcome unexpected, so new therapeutic targets for breast cancer need to be continuously discovered. In recent years, SLC7A5, as an amino acid transporter, plays a key role in metabolic reprogramming and immune microenvironment remodeling in breast cancer by regulating the uptake of glutamine and leucine. Although, the role of SLC7A5 in endocrine therapy resistance is still unclear, small molecule inhibitors targeting its function such as JPH203 have shown significant efficacies in preclinical models. This article reviews the structure and function of SLC7A5, its expression characteristics in breast cancer, and its molecular mechanism driving tumor progression, and discusses the therapeutic strategies targeting SLC7A5 and its potential for clinical translation.
